Study:
European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor
cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of
chemotherapy and kill more tumor cells. It is not yet known if combination chemotherapy is
more effective with or without radiation therapy and/or surgery in treating Ewing`s sarcoma.
Purpose:
This randomized phase III trial is studying different combination chemotherapy
regimens to see how well they work when given with or without peripheral stem cell
transplantation, radiation therapy, and/or surgery in treating patients with Ewing`s
sarcoma.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Sarcoma |
Biological: dactinomycin
Drug: busulfan
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Drug: vincristine sulfate
Procedure: autologous hematopoietic stem cell transplantation
Procedure: conventional surgery
Radiation: radiation therapy |
Phase 3 |
Verified by
University Hospitals, Leicester
December, 2011
Sponsored by: University Hospitals, Leicester
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00020566
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Alan W. Craft, MD., Study Chair
Ian J. Lewis, MD., Study Chair
Odile Oberlin, MD., Study Chair
Ian R. Judson, MA, MD, FRCP.,
Heribert F. Juergens, MD., Study Chair
Helmut Gadner, MD, FRCPG., Study Chair
G. Ulrich Exner, MD., Study Chair
Ruth Ladenstein, MD., Study Chair
Douglas Hawkins, MD., Study Chair